Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RANOPTO - Health Canada Drug Approval Details

Approvals/Health Canada/RANOPTO

Authorized

STANDARD

RANOPTO

teva canada limited🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: ef543861db057425
Company: teva canada limited
Type: Standard

Approval Details

Approval Id: ef543861db057425
Drug Approval Canada Name: RANOPTO
Product Name: RANOPTO
Status: Marketed
Status Date: 2024-02-26
Original Market Date: 2024-02-26
Din: 02542250
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravitreal
Schedule: Prescription , Schedule D
Ahfs: 52:92.00
Atc Original: S01LA04 RANIBIZUMAB
Atc Name: s 01 la 04
Aig Number: 0152224001
Company Name: teva canada limited
Company Address: 30 Novopharm Court, Toronto, Ontario, Canada, M1B 2K9

Active Ingredients

RANIBIZUMAB

10 MG / ML

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

ef543861db057425

Type

Standard

Back to Health Canada Approvals